Evidence map›Paper›PMID 30917314›Full record

ArticleCell reports2019

Tuberculosis Exacerbates HIV-1 Infection through IL-10/STAT3-Dependent Tunneling Nanotube Formation in Macrophages.

Shanti Souriant, Luciana Balboa, Maeva Dupont, Karine Pingris, Denise Kviatcovsky, Céline Cougoule, Claire Lastrucci, Aicha Bah, Romain Gasser, Renaud Poincloux and 17 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 4 countries.

Shanti SouriantInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina.
Luciana BalboaInternational Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina; Institute of Experimental Medicine-CONICET, National Academy of Medicine, Buenos Aires, Argentina.
Maeva DupontInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina.
Karine PingrisInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Denise KviatcovskyInternational Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina; Institute of Experimental Medicine-CONICET, National Academy of Medicine, Buenos Aires, Argentina.
Céline CougouleInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina.
Claire LastrucciInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; Centre for Genomic Regulation, Barcelona, Spain.
Aicha BahInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Romain GasserCentre de Physiopathologie de Toulouse Purpan, INSERM UMR 1043, CNRS UMR 5282, Université Toulouse III Paul Sabatier, Toulouse, France.
Renaud PoinclouxInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Brigitte Raynaud-MessinaInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Talal Al SaatiINSERM/UPS/ENVT-US006/CREFRE, Service d'Histopathologie, CHU Purpan, 31024 Toulouse, France.
Sandra InwentarzInstituto de Tisioneumonologia "Raúl F. Vaccarezza," Universitad de Buenos Aires, Argentina.
Susana PoggiInstituto de Tisioneumonologia "Raúl F. Vaccarezza," Universitad de Buenos Aires, Argentina.
Eduardo Jose MorañaInstituto de Tisioneumonologia "Raúl F. Vaccarezza," Universitad de Buenos Aires, Argentina.
Pablo González-MontanerInstituto de Tisioneumonologia "Raúl F. Vaccarezza," Universitad de Buenos Aires, Argentina.
Marcelo CortiDivision de SIDA, Hospital de Infecciosas Dr. F.J. Muñiz, Buenos Aires, Argentina.
Bernard LaganeCentre de Physiopathologie de Toulouse Purpan, INSERM UMR 1043, CNRS UMR 5282, Université Toulouse III Paul Sabatier, Toulouse, France.
Isabelle VergneInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Carolina AllersTulane National Primate Research Center, Covington, LA 70433, USA; Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Deepak KaushalTulane National Primate Research Center, Covington, LA 70433, USA; Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Marcelo J KurodaTulane National Primate Research Center, Covington, LA 70433, USA; Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Maria Del Carmen SasiainInternational Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina; Institute of Experimental Medicine-CONICET, National Academy of Medicine, Buenos Aires, Argentina.
Olivier NeyrollesInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina.
Isabelle Maridonneau-PariniInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina.
Geanncarlo Lugo-VillarinoInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina. Electronic address: lugo@ipbs.fr.
Christel VérolletInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International Associated Laboratory (LIA) CNRS "IM-TB/HIV" (1167), Toulouse, France, and Buenos Aires, Argentina. Electronic address: verollet@ipbs.fr.
Centre National de la Recherche Scientifique · FRUniversidad de Buenos Aires · ARTulane University · USHospital Muñiz · ARUniversité Toulouse III - Paul Sabatier · FR

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
BAA-NIH-NIAID-NCRR-DMID-03-036UC6AI058609 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI LACKNER, ANDREW A · 2003 to 2006
$21.1M
Macrophages in the pathogenesis of AIDSR01AI097059 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KURODA, MARCELO J · 2012 to 2016
$4.0M
Targeting HIV Lung Reservoir in the Macaque ModelR33AI110163 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KURODA, MARCELO J · 2016 to 2018
$1.5M
Targeting HIV Lung Reservoir in the Macaque ModelR21AI110163 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KURODA, MARCELO J · 2014 to 2015
$457k
NIAID NIH HHS R01 AI097059NIAID NIH HHS R21 AI110163NIAID NIH HHS R33 AI110163NIAID NIH HHS UC6 AI058609NIH HHS P51 OD011104NIH HHS P51 OD011107
6 · The paper itself

Abstract

The tuberculosis (TB) bacillus, Mycobacterium tuberculosis (Mtb), and HIV-1 act synergistically; however, the mechanisms by which Mtb exacerbates HIV-1 pathogenesis are not well known. Using in vitro and ex vivo cell culture systems, we show that human M(IL-10) anti-inflammatory macrophages, present in TB-associated microenvironment, produce high levels of HIV-1. In vivo, M(IL-10) macrophages are expanded in lungs of co-infected non-human primates, which correlates with disease severity. Furthermore, HIV-1/Mtb co-infected patients display an accumulation of M(IL-10) macrophage markers (soluble CD163 and MerTK). These M(IL-10) macrophages form direct cell-to-cell bridges, which we identified as tunneling nanotubes (TNTs) involved in viral transfer. TNT formation requires the IL-10/STAT3 signaling pathway, and targeted inhibition of TNTs substantially reduces the enhancement of HIV-1 cell-to-cell transfer and overproduction in M(IL-10) macrophages. Our study reveals that TNTs facilitate viral transfer and amplification, thereby promoting TNT formation as a mechanism to be explored in TB/AIDS potential therapeutics.

Indexed as

NanotubesAdultAgedAnimalsCells, CulturedCoinfectionFemaleHIV InfectionsHumansInterleukin-10Macaca mulattaMacrophage ActivationMacrophagesMaleMiddle AgedMycobacterium tuberculosisIL10 protein, humanInterleukin-10STAT3 protein, humanSTAT3 Transcription FactorAIDSbiomarkerco-infectionHIV-1IL-10macrophagemonocyteMycobacterium tuberculosisSTAT3tuberculosistunneling nanotubesviral spread

Identifiers

PMID30917314
PMCPMC6733268
OpenAlexW2924456799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.